TEL AVIV, Israel and BETHESDA, Md., October 20, 2021 / PRNewswire / – Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer-related cannabinoid-based drugs, announced today that Dr. Inbar Maymon-Pomeranchik, director of the company, at MjBizCon in. will attend Las Vegas on 20.-22. October 2021.
CNBX director, Dr. Inbar Maymon-Pomeranchik (PRNewsfoto / Cannabics Pharmaceuticals Inc.)
Dr. Maymon-Pomeranchik will attend the regulatory panel meeting and will be available for one-on-one discussions after the meeting to further discuss our lead colon cancer drug candidate, RCC-33. Those interested in getting in touch with Cannabics Pharmaceuticals, CNBX, should contact us at: [email protected].
Continue reading:
Recent addition to the company’s IP portfolio with filing of 2 new provisional patents; The latest addition to the Advisory Board of Cannabics Pharmaceuticals: Prof. Caroline Robert (MD, Ph.D.), a melanoma expert, and Dr. Sigal Tavor (MD), a hematology expert, together with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. D.) and Dr. Tal Mofkadi (Ph.D.); The latest addition to the Board of Directors of Cannabics Pharmaceuticals: Dr. Inbar Maymon-Pomeranchik (Ph.D.) and Dr. Gil Feiler (Ph.D.) as independent directors.
About cannabis pharmaceuticals:
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a US public company and a global leader in the development of cancer-related cannabinoid drugs. The company’s research and development is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. More information is available at http://www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals, follow the company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and Instagram @Cannabics_Pharmaceuticals.
Disclaimer:
Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other US securities laws. Such statements include, among other things, statements identified by the words “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “aims,” ”projects” and similar expressions. The statements in this press release are based on the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results could differ from the forward-looking statements. Numerous factors can cause or contribute to such differences, including but not limited to the results of clinical trials and other studies, the challenges associated with new product development initiatives, the impact of competitive products, our ability to license and protect our intellectual property, ours Ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulations, potential litigation by or against us, any government review of our products or practices, and other risks that may be discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q report dated July 14, 2021. We assume no obligation, forward-looking statements or information in this press release Update ilung or other public releases at any time. Finally, the investor audience is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. that the company tolerates must come from the company itself and bear our name as the source.
More information on cannabis:
Cannabis Pharmaceuticals Inc.
+1 (877) 424-2429
[email protected]
https://www.cannabics.com
Photo – https://mma.prnewswire.com/media/1665620/CNBX_Maymon_Pomeranchik.jpg
SOURCE Cannabics Pharmaceuticals Inc.
